Evidence map›Paper›PMID 37391548›Full record

ArticleArchives of microbiology2023

Inactivation of SARS-CoV-2 on salt-coated surfaces: an in vitro study.

Monika Gsell, Xavier Bulliard, Sandra Schorderet Weber, Yang Xiang, Samuel Constant, Sandro Steiner, Silvia Biselli, Raphael Pugin, Michele Palmieri, Andreas Hogg and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Archives of microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Monika GsellInstitute for Infectious Diseases, University of Berne, 3010, Bern, Switzerland. monika.gsell@unibe.ch.
Xavier BulliardCentre Suisse d'Electronique et de Microtechnique SA (CSEM), Rue Jaquet-Droz 1, 2002, Neuchâtel, Switzerland.
Sandra Schorderet WeberPMI R&D, Philip Morris Products S.A., Quai Jeanreaud 5, 2000, Neuchâtel, Switzerland.ORCID http://orcid.org/0000-0003-1100-4210
Yang XiangPMI R&D, Philip Morris Products S.A., Quai Jeanreaud 5, 2000, Neuchâtel, Switzerland.ORCID http://orcid.org/0000-0001-7750-9129
Samuel ConstantEpithelix Sàrl, Chemmin des Aulx 18, Plan-Les-Ouates, 1228, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-0931-2663
Sandro SteinerPMI R&D, Philip Morris Products S.A., Quai Jeanreaud 5, 2000, Neuchâtel, Switzerland.ORCID http://orcid.org/0000-0002-9413-9067
Silvia BiselliCentre Suisse d'Electronique et de Microtechnique SA (CSEM), Rue Jaquet-Droz 1, 2002, Neuchâtel, Switzerland.
Raphael PuginCentre Suisse d'Electronique et de Microtechnique SA (CSEM), Rue Jaquet-Droz 1, 2002, Neuchâtel, Switzerland.
Michele PalmieriCentre Suisse d'Electronique et de Microtechnique SA (CSEM), Rue Jaquet-Droz 1, 2002, Neuchâtel, Switzerland.
Andreas HoggCoat-X SA, Eplatures-Grise 17, 2900, La Chaux-de-Fonds, Switzerland.
Manuel C PeitschPMI R&D, Philip Morris Products S.A., Quai Jeanreaud 5, 2000, Neuchâtel, Switzerland.ORCID http://orcid.org/0000-0001-5324-359X
Julia HoengPMI R&D, Philip Morris Products S.A., Quai Jeanreaud 5, 2000, Neuchâtel, Switzerland.ORCID http://orcid.org/0000-0001-5371-6801
Adrian StanPMI R&D, Philip Morris Products S.A., Quai Jeanreaud 5, 2000, Neuchâtel, Switzerland.ORCID http://orcid.org/0000-0003-3276-3515
Philip Morris International (Switzerland) · CHSwiss Center for Electronics and Microtechnology (Switzerland) · CHGenkyotex (Switzerland) · CHUniversity of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), face masks have become a very important safety measure against the main route of transmission of the virus: droplets and aerosols. Concerns that masks contaminated with SARS-CoV-2 infectious particles could be a risk for self-contamination have emerged early in the pandemic as well as solutions to mitigate this risk. The coating of masks with sodium chloride, an antiviral and non-hazardous to health chemical, could be an option for reusable masks. To assess the antiviral properties of salt coatings deposited onto common fabrics by spraying and dipping, the present study established an in vitro bioassay using three-dimensional airway epithelial cell cultures and SARS-CoV-2 virus. Virus particles were given directly on salt-coated material, collected, and added to the cell cultures. Infectious virus particles were measured by plaque forming unit assay and in parallel viral genome copies were quantified over time. Relative to noncoated material, the sodium chloride coating significantly reduced virus replication, confirming the effectiveness of the method to prevent fomite contamination with SARS-CoV-2. In addition, the lung epithelia bioassay proved to be suitable for future evaluation of novel antiviral coatings.

Indexed as

COVID-19Sodium ChlorideAntiviral AgentsHumansPandemicsSARS-CoV-2Antiviral AgentsSodium Chloride3D lung cell cultureAntiviral coatingCOVIDFace masksSARS-CoV-2

Identifiers

PMID37391548
PMCPMC10313567
OpenAlexW4382677485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.